TN SB2255AI summary is being generated. Check back soon for a plain-language breakdown of this bill.
Positive media analysis is being generated.
Critical media analysis is being generated.
The analysis of SB2255, which focuses on the regulation and reporting of psychotropic medication use in Tennessee, reveals no direct conflicts of interest for the sponsor, Brent Taylor. His primary occupation as an attorney and his involvement with the Taylor Law Firm do not intersect with the pharmaceutical or healthcare industries that would be directly impacted by this legislation. Additionally, while he is associated with UBS Investments, there is no indication that this role involves direct investments in psychotropic medications or related healthcare services that would benefit from the bill's provisions.
Unlike federal analysis based on campaign donations, state analysis examines legislators' personal financial interests — their jobs, businesses, and investments.
| Type | Description | Industry | Source |
|---|---|---|---|
| Occupation | Attorney | Lawyers/Law Firms | TN Legislature bio |
| Employer | Taylor Law Firm | Lawyers/Law Firms | AI-researched |
| Board Member | Board Member of the Memphis City Council | — | AI-researched |
| Employer | UBS INVESTMENTS | — | TN Ethics Commission |
| Occupation | Other, FUNERAL SERVICES | — | TN Ethics Commission |
Items marked "AI-researched" are generated from public sources but have not been independently verified. Verified data is sourced from official legislature websites and disclosure filings.
About This Analysis
This summary was generated using AI from the bill's official text and metadata. Data sourced from LegiScan and the Tennessee General Assembly. Conflict analysis examines the sponsor's personal financial interests for potential overlaps with the bill's subject matter.
